help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beaulieu, M.
Right arrow Articles by Cote, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beaulieu, M.
Right arrow Articles by Cote, T. E.

Endocrinology, Vol 114, 1871-1884, Copyright © 1984 by Endocrine Society

ARTICLES

Bromocriptine-induced changes in the biochemistry, physiology, and histology of the intermediate lobe of the rat pituitary gland

M Beaulieu, ME Goldman, K Miyazaki, EA Frey, RL Eskay, JW Kebabian and TE Cote

Treatment of rats with 2-Br-alpha-ergocryptine (bromocriptine; CB 154) elicits biochemical, physiological, and histological changes in the intermediate lobe (IL) of the rat pituitary gland, suggesting a decrease in activity in the IL. CB 154 treatment decreases 1) the capacity of the IL to synthesize proopiomelanocortin (POMC), 2) the content of mRNA directing the synthesis of POMC, and 3) the capacity of the IL to synthesize the peptides desacetyl alpha MSH, N,O-diacetyl alpha MSH, and alpha MSH. CB 154 treatment also causes a 40% loss of IL protein and an atrophy of the IL. CB 154 treatment has a biphasic effect upon the IL content of alpha MSH-like peptides; the drug first increases and then diminishes the content of these molecules. Control experiments using CB 154-treated IL tissue suggest that these effects of CB 154 are not a toxic effect of CB 154 on the IL. Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH. Stalk section of rat pituitary gland also results in an increase in the capacity of the IL to synthesize POMC. These results suggest that a D-2 dopamine receptor mediates a tonic inhibition of the function of the IL.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
S.-N. Lee, B. Peng, R. Desjardins, J. E Pintar, R. Day, and I. Lindberg
Strain-specific steroidal control of pituitary function
J. Endocrinol., March 1, 2007; 192(3): 515 - 525.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. L. González de Aguilar, M. M. Malagón, R. M. Vázquez-Martínez, A. J. Martínez-Fuentes, M. C. Tonon, H. Vaudry, and F. Gracia-Navarro
Differential Effects of Dopamine on Two Frog Melanotrope Cell Subpopulations
Endocrinology, January 1, 1999; 140(1): 159 - 164.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
M. R. Schiller, R. E. Mains, and B. A. Eipper
A Novel Neuroendocrine Intracellular Signaling Pathway
Mol. Endocrinol., November 1, 1997; 11(12): 1846 - 1857.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society